Cardiology Department, Santa Marta Hospital, Centro Hospitalar Universitário Lisboa Central, Rua Santa Marta, 1169-025, Lisbon, Portugal.
NOVA Medical School, Lisbon, Portugal.
Heart Fail Rev. 2023 Sep;28(5):1053-1063. doi: 10.1007/s10741-023-10297-3. Epub 2023 Feb 4.
Refractory congestive heart failure (RCHF) is a common complication in the natural history of advanced heart failure. Peritoneal dialysis (PD) is a possible alternative in those patients, but studies are scarce, and mostly with small samples. We conducted this meta-analysis to evaluate the effects of PD in patients with RCHF. Articles published before July 2020 in the following databases: PubMed, Web of Science, and CENTRAL. Mean differences (MD) and 95% confidence intervals (CIs) were computed to generate a pooled effect size with a random effects model. We also assessed heterogeneity, risk of bias, publication bias, and quality of evidence. Twenty observational studies (n = 769) were included, with a "before and after intervention" design. PD was associated with a significant reduction in NYHA functional class (MD -1.37, 95% CI -0.78 to -1.96) and length of hospitalisation (MD -34.8, 95% CI -20.6 to -48.9 days/patient/year), a small but significant increase in left ventricular ejection fraction (MD 4.3, 95%CI 1.9 to 6.8%) and a non-significant change in glomerular filtration rate (MD -3.0, 95% CI -6.0 to 0 mL/min/1.73m2). Heterogeneity among studies was significant and overall risk of bias was rated from moderate to critical. No significant publication bias was found, and the overall quality of evidence was very low for all outcomes. PD in patients with RCHF improved functional class, length of hospitalisation, and ventricular functional, and had no impact in renal function. Further randomised clinical trials are warranted to confirm our results that showed some limitations.
难治性充血性心力衰竭(RCHF)是晚期心力衰竭自然病程中的常见并发症。对于这些患者,腹膜透析(PD)可能是一种替代方法,但研究很少,而且大多样本量较小。我们进行了这项荟萃分析,以评估 PD 在 RCHF 患者中的疗效。检索了 2020 年 7 月前在以下数据库发表的文章:PubMed、Web of Science 和 CENTRAL。采用随机效应模型计算均数差(MD)和 95%置信区间(CI)以得出汇总效应量。我们还评估了异质性、偏倚风险、发表偏倚和证据质量。纳入了 20 项观察性研究(n=769),采用“干预前后”设计。PD 与 NYHA 心功能分级显著降低(MD-1.37,95%CI-0.78 至-1.96)和住院时间缩短(MD-34.8,95%CI-20.6 至-48.9 天/患者/年)相关,左心室射血分数略有但显著增加(MD 4.3,95%CI 1.9 至 6.8%),肾小球滤过率无显著变化(MD-3.0,95%CI-6.0 至 0 mL/min/1.73m2)。研究间存在显著异质性,总体偏倚风险评分为中度至高度。未发现显著发表偏倚,所有结局的总体证据质量均非常低。PD 可改善 RCHF 患者的心功能分级、住院时间和心室功能,但对肾功能无影响。需要进一步的随机临床试验来证实我们的结果,这些结果显示出一些局限性。